Radiofrequency Ablation Devices Market Size

Industry Report and Statistics (Facts & Figures) - Sales Volume, ASP & Number of Procedure Conducted by Product & Application

The global radiofrequency ablation devices market will witness a robust CAGR of 11.32%, valued at $3.9 billion in 2021, expected to appreciate and reach $10.7 billion by 2030, confirms Strategic Market Research. Radio Frequency Ablation (RFA) or fulguration is a MI (minimal invasive) process that is involved with the ablation of dysfunctional tissues via the heat generated from alternating current with a frequency range of (350 to 500 kHz).RFA uses CT (Computed Tomography), MRI (Magnetic resonance Imaging), and Ultrasound devices to assist the needle electrode into a cancerous tumour. This process is also widely used for the treatment of cardiovascular diseases and pain management. According to WHO, cardiovascular disease (CVD) is the major cause of death around the world. Approximately 17.9 Mn people died from cardiovascular diseases in the year 2019, representing almost 32% of the total deaths worldwide. Out of these deaths, approximately 85% were due to stroke and heart attack. Also, in 2019, out of the 17 Mn premature deaths (people aged under 70 years) that had occurred due to non-communicable diseases, 38% of them were caused due to CVDs.

Also, according to WHO, Cancer is one of the leading causes of death across the globe resulting in close to 10 Mn deaths in the year 2020. Breast Cancer recorded the highest number of new cases in 2020 with 2.26 Mn cases followed by Lung Cancer (2.21 Mn cases), colon and rectum cancer (1.93 Mn cases), prostate cancer (1.41 Mn cases), skin (non-melanoma) cancer (1.20 Mn cases) and stomach cancer (1.09 Mn cases). Lung Cancer still remained the leading cause of death in 2020, with 1.80 Mn deaths followed by colon and rectum cancer (9,35,000 deaths), liver cancer (8,30,000 deaths), stomach cancer (7,69,000 deaths), and breast cancer (6,85,000 deaths). All of the aforesaid statistics are highly estimated to accelerate the overall growth of the global radiofrequency ablation devices market throughout the estimated duration of 2021 - 2030.

Key Industry Drivers

The increase in the number of cases of cardiovascular diseases and cancer (Lung Cancer, liver cancer, kidney cancer, bone cancer, hepatocellular carcinoma, pancreatic cancer, bile duct cancer, etc) across the globe is one of the pivotal causes that is fuelling the overall growth of the market. The cardiac ablation is growing steadily with a CAGR of 12.78% along with overall revenue of USD 996.173 Mn, which in turn is driving the market growth significantly.

Apart from the rising number of cases of cancer and CVDs, the rise in demand for pain management (such as relief from arthritis and other chronic pain disorders by medicines) is also propelling the overall market growth to a great extent. The market is growing smoothly at a CAGR of 5.017 % throughout the forecasted duration of 2020-2030.

Also, geriatric people are more prone to chronic diseases, and the continuous growth in the geriatric population worldwide is one of the pivotal factors that is fuelling the growth of the market. According to the World Health Organization, the number of people who are aged 60 years and above will increase from 900 Mn to 2Bn between the year 2015 to 2050.

Apart from the geriatric population growth across the globe, the increasing prevalence in the number of metastatic bone diseases, osteoid osteomas, Multifocal Atrial Tachycardia, ventricular arrhythmia, supraventricular tachycardia, Renal sympathetic denervation, Hypertension, Varicose veins treatment, Obstructive sleep apnea, balloon-based radiofrequency ablation, uterine fibroids, lumbar radiofrequency ablation success rate, radiofrequency ablation for back pain, usage of local anaesthetics, radiofrequency catheter ablation, CT scan, are widely driving the overall radiofrequency ablation devices market growth worldwide.

Restraints

Damage to the nerve and surrounding blood vessels due to needle insertions, hyperesthesia, damage to the structures that are situated adjacent to the target nerve, muscular tissue damage, and excess itching at the injection site are the major factors that are highly obstructing the growth of the market.

Opportunities

Advantages in RFA of Cardiac Arrhythmiaacross the globe have opened new possibilities for procedural safety. The advent of both ICE imaging and EAM techniques has highly improved the RFA devices' ability to treat arrhythmia with or without the usage of Fluoroscopy. Hence, its demand is estimated to grow at an exponential rate in the future.

Market Analysis Of Different Segments Covered in the Report

Based on Product:

RF Generators

Disposables

Cannulas

Needles

Reusables

Probes

Electrodes

Based on Applications

Surgical Oncology

Pain Management

Cardiology & Cardiac Rhythm Management

Cosmetology

Gynaecology

Others

Based on End-User

Hospitals

Ambulatory Surgical Centers

Others

Regional Coverage Analysis

North America

US

Mexico

Canada

Rest of North America

Europe

Switzerland

Russia

France

Germany

U.K

Finland

Turkey

Netherlands

Belgium

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Indonesia

South Korea

Thailand

Japan

Singapore

Malaysia

Philippines

Australia

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

Uruguay

Argentina

Rest of LAMEA

Product Analysis & Insights

The disposable segment dominated the market in 2020 with a steady CAGR. The reduction of morbidity and mortality rates worldwide and the ability of the RFA devices for providing treatment in an outpatient setting are propelling the overall growth of this segment.

Applications Analysis & Insights

The ‘Surgical Oncology’ segment dominated the market in 2020. The primary aim of surgical oncology is to remove the cancerous tissues that are present in the body (Surgical Biopsy). According to BIBB INSTRUMENTS, over 1 Mn biopsies are conducted each year across the globe with the help of EUS fine-needle instruments. In the U.S itself, there are over 1200 hospitals that are implementing endoscopy ultrasound to diagnose cancer patients.

End-User Analysis & Insights

The ‘Hospitals’ segment comprehensively dominated the radiofrequency ablation devices market in 2020 and will continue to do so during the forecasted period of 2020-2030. According to DEFINITIVE HEALTHCARE, the hospitals in the United States spent a total of USD 36 billion on medical supplies in the year 2018, with an average of almost USD 11.9 Mn per hospital.

Region Analysis & Insights

North America dominated the market with a CAGR of 11.973% and overall revenue of 1.513 billion in 2020. Rapid technological advancements in RFA and other medical devices, the continuous increasing prevalence of cancer cases, and higher expenditure by the governments on healthcare facilities are widely stimulating the overall growth of this market.

However, the Asia-Pacific region held the fastest CAGR throughout the estimated period of 2020-2030. The introduction of new technology like multi-needle electrodes and the rapid improvements of healthcare infrastructures in China and India are widely stimulating the growth of the market in this region.

Radiofrequency Ablation Devices Market Report Coverage

Report Attribute

Details

Forecast Period

2021 - 2030

Market size value in 2021

USD 3.9 billion

Revenue forecast in 2030

USD 10.7 billion

Growth rate

CAGR of approximately 11.73%

Base year for estimation

2021

Historical data

2017 – 2020

Unit

USD Billion, CAGR (2021 - 2030)

Segmentation

By Product, By Applications, By End-User, By Region

By Product

RF Generators, Disposables(Cannulas,Needles) Reusables(Probes,Electrodes)

By Applications

Surgical Oncology, Pain Management, Cardiology & Cardiac Rhythm Management, Cosmetology, Gynaecology, Others

By End-User

Hospitals, Ambulatory Surgical Centers, Others

By Region

North America, Europe, Asia-Pacific, LAMEA.

Country Scope

U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc.

Company Usability Profiles

Halyard Healt, Boston Scientific Corporatiom, St. Jude Medical, Medtronic Plc, Stryker Corporation, C. R. Bard, Hologi, AtriCur, AngioDynamic , Johnson & Johnso, Baylis Medica , Arthre, Inomed Medizintechnik GmbH, Bramsys Indústria e ComércioLtda , ENDO-FLEX GmbH , Sutter Medizintechnik Gmbh, Epimed International, Sfm Medical Devices Gmbh

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs.

Radiofrequency Ablation Devices Market Report Coverage

The competitive landscape analysis provides up-to-date information regarding the key competitors prevailing in the market environment worldwide. The comparison is performed based on company overview, market potential, investment in research and development, total revenue generated, company financials, global presence, production capacities, market initiatives, company strengths and weaknesses, production sites and facilities, etc.

Halyard Health

Boston Scientific Corporation

St. Jude Medical

Medtronic Plc

Stryker Corporation

C. R. Bard

Hologic

AtriCure

AngioDynamics

Johnson & Johnson

Baylis Medical

Arthrex

Inomed Medizintechnik GmbH

Bramsys Indústria e ComércioLtda

ENDO-FLEX GmbH

Sutter Medizintechnik Gmbh

Epimed International

Sfm Medical Devices Gmbh

Recent Developments

On June 2020, Boston Scientific launched DIRECTSENSE Technology, which provided the electrophysiologists with the first-ever local measurement and visualization of the tissue responses to RFA.

On Feb 2019, Medtronic received FDA clearance of launching the Accurian(TM) radiofrequency ablation platform, which is highly efficient in conducting RF ablation of nerve tissues.

On Apr 2021, AtriCure received FDA approval for launching its Epi sense system for the treatment purposes of patients who are diagnosed with long-standing and persistent Atrial Fibrillation. According to the National Library of Medicine, Atrial fibrillation is one of the most frequent types of cardiac arrhythmia. It has been anticipated that approximately (6 to 12) Mn people across the globe will suffer from this condition in the United States by the year 2050 and almost 17.9 Mn people in Europe by the year 2060.

Various Product Developed by Key Market Players

Product

Function

Company

RF 3000 Radiofrequency Generator

Delivers an isolated radiofrequency output of almost 200W to the electrode.

Boston Scientific Corporation

VAPR VUE RF Electrode System

It is designed for providing efficient soft tissue ablation and hemostasis of blood vessels at the time of arthroscopic surgery.

Johnson & Johnson

Barrx RFA System

Involves the usage of a bipolar RF energy generator that is designed to maintain the uniformity of tissue ablations in the Gastrointestinal tract.

Medtronic

MultiGen 2 Radio Frequency Generator

It was upgraded with some of the most modern features, like a lifecycle tracker for electrode usage, an ultra-responsive touchscreen, and a USB port to save and transfer vital data.

Stryker Corporation

Frequently Asked Question About This Report

The dominating players in the global RF ablation devices market areHalyard Health, Boston Scientific Corporation, St. Jude Medical, Medtronic Plc, Stryker Corporation, C. R. Bard, Hologic, AtriCure, AngioDynamics, Johnson & Johnson, Baylis Medical, Arthrex, Inomed Medizintechnik GmbH, Bramsys Indústria e Comércio Ltd, ENDO-FLEX GmbH, Sutter Medizintechnik Gmbh, Epimed International, and Sfm Medical Devices Gmbh.

North America has the highest share in the Global market with a CAGR of 11.973% and overall revenue of 1.513 billion in 2020.

The global radiofrequency ablation devices market is expected to grow at a compound annual growth rate (CAGR) of 11.732% from 2021 to 2030 to reach USD10.70 billion by 2030.

The global radiofrequency ablation devices market size was $3.94 Bn in 2021 and is predicted to reach $10.70 Bn by 2030, with a CAGR of 11.732%.

The “Hospitals’ segment is the major end-user of the market.

The key drivers of the global RF ablation devices market are the rising prevalence of the number of cases of CVDs and cancer across the globe, the continuous growth of the geriatric population, and the rise in demand for pain management.

Sources

https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

https://www.bibbinstruments.com/en/about-bibb/needs-and-market/

https://www.definitivehc.com/resources/healthcare-insights/changes-in-supply-costs-year-to-year

https://news.bostonscientific.com/2020-06-01-Boston-Scientific-Launches-DIRECTSENSE-TM-Technology

1. Introduction

1.1. Study Objective

1.2. Market Definition

1.3. Study Scope

1.3.1. Markets Covered

1.3.2. Geographic Scope

1.3.3. Years Considered

1.3.4. Stakeholders

2. Research Methodology

2.1. Data Procurement

2.2. Paid Database

2.2.1. Secondary Data

2.2.1.1. Key Secondary sources

2.2.2. Primary Data

1.2.2.1 Primary sources

2.1.2.2. Key industry insights

2.1.2.3. Primary interviews with experts

2.1.2.4. Key primary respondent list

2.2. Market Size Estimation

2.3. Bottom-Up and Top-Down Approaches

2.4.1. Bottom-Up Approach

2.4.1.1. Approach for arriving at market size by bottom-up analysis

2.4.2. Top-Down Approach

2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis

2.4. Market Breakdown and Data Triangulation

2.5. Research Methodology

2.6. Risk Assessment

3. Executive Summary

3.1 Radio Frequency Ablation Devices Market: Post-Covid-19

3.1.1 Actual Scenario

3.1.2 Pessimistic Scenario

3.1.3 Optimistic Scenario

3.1.4 Market Summary

4. Industry Outlook

4.1 Market Snapshot

4.2 Global Radio Frequency Ablation Devices Market

4.2.1 Global Radio Frequency Ablation Devices Market, 2020 – 2028 (USD Million)

4.3 Regional Business Analysis

4.3.1 Market, by region, 2021-2030 (USD Million)

4.4 Based on Product Business Analysis

4.4.1 Market, Based on Product, 2021-2030 (USD Million)

4.5 Based on End-User Business Analysis

4.5.1 Market, Based on End-User, 2021-2030 (USD Million)

4.6 Application Business Analysis

4.6.1 Market, By Application, 2021-2030 (USD Million)

4.8 Value Chain Analysis

4.9 Market Variable Analysis

4.9.1 Market Drivers Analysis

4.9.2 Market Restraints Analysis

4.10 Business Environment Analysis Tool

4.10.1 Market PEST analysis

4.10.2 Market Porter’s analysis

4.11 Penetration & Growth Prospect Mapping

5. Market Dynamics

5.1. Introduction

5.2. Market Dynamics

5.2.1. Drivers

5.2.2. Restraints

5.2.3. Opportunities

5.2.4. Challenges

5.3. Impact of Covid-19 On Market

5.4. Value Chain Analysis

5.5. Ecosystem

5.6. Patent Analysis

5.7. Trade Analysis

5.8. Tariff Analysis

5.9. Case Study Analysis

5.10. Porter’s Five Forces Analysis

5.10.1 Threat of New Entrants

5.10.2 Threat of Substitutes

5.10.3 Bargaining Power of Buyers

5.10.4 Bargaining Power of Suppliers

5.10.5 Degree of Competition

5.11. Technology Analysis

5.11.1. Trends in Technology (2014-2020)

5.11.2. Trends in Technology (2021-2028)

5.12. Pricing Analysis

5.12.1. Average Price Trend Analysis (By region, By Countries)

6. Competitive & Vendor Landscape

6.1. Company Market Share Analysis

6.2. Market Competitive Situation and Trends

6.3. Manufacturers Mergers & Acquisitions, Expansion Plans

7. Global Radiofrequency Ablation Devices Market: Based on Product Segment Analysis

7.1. Introduction

7.2. Sales Volume & Revenue Analysis (2021-2030)

7.3. RF Generators

7.3.1. RF Generators market, 2021-2030 (USD Million)

7.4. Disposables

7.4.1. Disposables market, 2021-2030 (USD Million)

7.5. Cannulas

7.5.1. Cannulas market, 2021-2030 (USD Million)

7.6. Needles

7.6.1. Needles market, 2021-2030 (USD Million)

7.7. Reusables

7.7.1. Reusables market, 2021-2030 (USD Million)

7.8. Probes

7.8.1. Probes market, 2021-2030 (USD Million)

7.9. Electrodes

7.8.1. Electrodes market, 2021-2030 (USD Million)

8. Global RadioFrequency Ablation Devices Market: Based on End-User Segment Analysis

8.1. Introduction

8.2. Sales Volume & Revenue Analysis (2021-2030)

8.3. Hospitals

8.3.1. Hospitals market, 2021-2030 (USD Million)

8.4. Ambulatory Surgical Centers

8.4.1. Ambulatory Surgical Centers market, 2021-2030 (USD Million)

8.5. Others

8.5.1. Others market, 2021-2030 (USD Million)

9. Global RadioFrequency Ablation Devices Market: By Application Segment Analysis

9.1. Introduction

9.2. Sales Volume & Revenue Analysis (2021-2030)

9.3. Surgical Oncology

9.3.1. Surgical Oncology market, 2021-2030 (USD Million)

9.4. Pain Management

9.4.1. Pain Management market, 2021-2030 (USD Million)

9.5 Cardiology & Cardiac Rhythm

9.5.1 Cardiology & Cardiac Rhythm market, 2021-2030 (USD Million)

9.6. Management

9.6.1. Management market, 2021-2030 (USD Million)

9.7. Cosmetology

9.7.1. Cosmetology market, 2021-2030 (USD Million)

9.8. Gynaecology

9.8.1. Gynaecology market, 2021-2030 (USD Million)

9.9. Others

9.9.1. Others market, 2021-2030 (USD Million)

10. Global RadioFrequency Ablation Devices Market: By Type Segment Analysis

10.1. Introduction

10.2. Sales Volume & Revenue Analysis (2021-2030)

10.3. Surgical Oncology

10.3.1. Surgical Oncology market, 2021-2030 (USD Million)

11. Global RadioFrequency Ablation Devices Market: Regional Outlook

11.1 North America

11.1.1. North America Market, Based on Product, 2021-2030 (USD Million)

11.1.2. North America Market, Based on End-User, 2021-2030 (USD Million)

11.1.3. North America Market, by Application, 2021-2030 (USD Million)

11.1.4. North America Market, by Country, 2021-2030 (USD Million)

11.1.4.1. U.S.

11.1.4.1.1. U.S. Market, Based on Product, 2021-2030 (USD Million)

11.1.4.1.2. U.S. Market, Based on End-User, 2021-2030 (USD Million)

11.1.4.1.3. U.S. Market, by Application, 2021-2030 (USD Million)

11.1.4.2. Canada

11.1.4.2.1. Canada Market, Based on Product, 2021-2030 (USD Million)

11.1.4.2.2. Canada Market, Based on End-User, 2021-2030 (USD Million)

11.1.4.2.3. Canada Market, by Application, 2021-2030 (USD Million)

11.2. Europe

11.2.1. Europe Market, Based on Product, 2021-2030 (USD Million)

11.2.2. Europe Market, Based on End-User, 2021-2030 (USD Million)

11.2.3. Europe Market, by Application, 2021-2030 (USD Million)

11.2.4. Europe Market, by country, 2021-2030 (USD Million)

11.2.4.1 U.K.

11.2.4.1.1. U.K. Market, Based on Product, 2021-2030 (USD Million)

11.2.4.1.2. U.K. Market, Based on End-User, 2021-2030 (USD Million)

11.2.4.1.3. U.K. Market, by Application, 2021-2030 (USD Million)

11.2.4.2. Germany

11.2.4.2.1. Germany Market, Based on Product, 2021-2030 (USD Million)

11.2.4.2.2. Germany Market, Based on End-User, 2021-2030 (USD Million)

11.2.4.2.3. Germany Market, by Application, 2021-2030 (USD Million)

11.2.4.3. France

11.2.4.3.1. France Market, Based on Product, 2021-2030 (USD Million)

11.2.4.3.2. France Market, Based on End-User, 2021-2030 (USD Million)

11.2.4.3.3. France Market, by Application, 2021-2030 (USD Million)

11.2.4.4. Rest of Europe

11.2.4.4.1. Rest of Europe Market, Based on Product, 2021-2030 (USD Million)

11.2.4.4.2. Rest of Europe Market, Based on End-User, 2021-2030 (USD Million)

11.2.4.4.3. Rest of Europe Market, by Application, 2021-2030 (USD Million)

11.3. Asia Pacific

11.3.1. Asia Pacific Market, Based on Product, 2021-2030 (USD Million)

11.3.2. Asia Pacific Market, Based on End-User, 2021-2030 (USD Million)

11.3.3. Asia Pacific Market, by Application, 2021-2030 (USD Million)

11.3.4. Asia Pacific Market, by country, 2021-2030 (USD Million)

11.3.4.1. China

11.3.4.1.1. China Market, Based on Product, 2021-2030 (USD Million)

11.3.4.1.2. China Market, Based on End-User, 2021-2030 (USD Million)

11.3.4.1.3. China Market, by Application, 2021-2030 (USD Million)

11.3.4.2. India

11.3.4.2.1. India Market, Based on Product, 2021-2030 (USD Million)

11.3.4.2.2. India Market, Based on End-User, 2021-2030 (USD Million)

11.3.4.2.3. India Market, by Application, 2021-2030 (USD Million)

11.3.4.3. Japan

11.3.4.3.1. Japan Market, Based on Product, 2021-2030 (USD Million)

11.3.4.3.2. Japan Market, Based on End-User, 2021-2030 (USD Million)

11.3.4.3.3. Japan Market, by Application, 2021-2030 (USD Million)

11.3.4.4. South Korea

11.3.4.4.1. South Korea Market, Based on Product, 2021-2030 (USD Million)

11.3.4.4.2. South Korea Market, Based on End-User, 2021-2030 (USD Million)

11.3.4.4.3. South Korea Market, by Application, 2021-2030 (USD Million)

11.3.4.5. Rest of ASIA PACIFIC

11.3.4.5.1. Rest of ASIA PACIFIC Market, Based on Product, 2021-2030 (USD Million)

11.3.4.5.2. Rest of ASIA PACIFIC Market, Based on End-User, 2021-2030 (USD Million)

11.3.4.5.3. Rest of ASIA PACIFIC Market, by Application, 2021-2030 (USD Million)

11.4. Latin America

11.4.1. Latin America Market, Based on Product, 2021-2030 (USD Million)

11.4.2. Latin America Market, Based on End-User, 2021-2030 (USD Million)

11.4.3. Latin America Market, by Application, 2021-2030 (USD Million)

11.4.4. Latin America Market, by country, 2021-2030 (USD Million)

11.4.4.1. Brazil

11.4.4.1.1. Brazil Market, Based on Product, 2021-2030 (USD Million)

11.4.4.1.2. Brazil Market, Based on End-User, 2021-2030 (USD Million)

11.4.4.1.3. Brazil Market, by Application, 2021-2030 (USD Million)

11.4.4.2. Mexico

11.4.4.2.1. Mexico Market, Based on Product, 2021-2030 (USD Million)

11.4.4.2.2. Mexico Market, Based on End-User, 2021-2030 (USD Million)

11.4.4.2.3. Mexico Market, by Application, 2021-2030 (USD Million)

11.4.4.3. Rest of the Latin America

11.4.4.3.1. Rest of the Latin America Market, Based on Product, 2021-2030 (USD Million)

11.4.4.3.2. Rest of the Latin America Market, Based on End-User, 2021-2030 (USD Million)

11.4.4.3.3. Rest of the Latin America Market, by Application, 2021-2030 (USD Million)

11.5. MEA

11.5.1. MEA Market, Based on Product, 2021-2030 (USD Million)

11.5.2. MEA Market, Based on End-User, 2021-2030 (USD Million)

11.5.3. MEA Market, by Application, 2021-2030 (USD Million)

12. Competitive Landscape

12.1 Halyard Health.

12.1.1. Company overview

12.1.2. Financial performance

12.1.3. Product Portfolio Analysis

12.1.4. Business Strategy & Recent Development

12.2. Boston Scientific Corporation.

12.2.1. Company overview

12.2.2. Financial performance

12.2.3. Product Portfolio Analysis

12.2.4. Business Strategy & Recent Development

12.3. St. Jude Medical.

12.3.1. Company overview

12.3.2. Financial performance

12.3.3. Product Portfolio Analysis

12.3.4. Business Strategy & Recent Development

12.4. Medtronic Plc.

12.4.1. Company overview

12.4.2. Financial performance

12.4.3. Product Portfolio Analysis

12.4.4. Business Strategy & Recent Development

12.5. Stryker Corporation.

12.5.1. Company overview

12.5.2. Financial performance

12.5.3. Product Portfolio Analysis

12.5.4. Business Strategy & Recent Development

12.6. C. R. Bard.

12.6.1. Company overview

12.6.2. Financial performance

12.6.3. Product Portfolio Analysis

12.6.4. Business Strategy & Recent Development

12.7. Hologic.

12.7.1. Company overview

12.7.2. Financial performance

12.7.3. Product Portfolio Analysis

12.7.4. Business Strategy & Recent Development

12.8. Angio Dynamics.

12.8.1. Company overview

12.8.2. Financial performance

12.8.3. Product Portfolio Analysis

12.8.4. Business Strategy & Recent Development

12.9. Johnson & Johnson.

12.9.1. Company overview

12.9.2. Financial performance

12.9.3. Product Portfolio Analysis

11.9.4. Business Strategy & Recent Development

12.10. Baylis Medical.

12.10.1. Company overview

12.10.2. Financial performance

12.10.3. Product Portfolio Analysis

12.10.4. Business Strategy & Recent Development

12.11. Arthrex.

12.11.1. Company overview

12.11.2. Financial performance

12.11.3. Product Portfolio Analysis

12.11.4. Business Strategy & Recent Development

12.12. Inomed Medizintechnik GmbH.

12.12.1. Company overview

12.12.2. Financial performance

12.12.3. Product Portfolio Analysis

12.12.4. Business Strategy & Recent Development

12.13. Bramsys Indústria e ComércioLtda.

12.13.1. Company overview

12.13.2. Financial performance